Novartis AG ($NVS) Stock Forecast: Up 3.5% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Novartis AG?

Novartis AG (NVS) is a multinational pharmaceutical company known for its innovative healthcare products and research initiatives. The company operates in various segments, including Innovative Medicines, Sandoz, and Alcon, offering a wide range of pharmaceuticals and healthcare solutions to global markets.

Why is Novartis AG going up?

NVS stock is up 3.5% on Jan 6, 2026 19:15

The bullish movement in Novartis AG (NVS) stock today is driven by increased institutional investment and positive sentiment from analysts following a recent earnings miss.
Institutional investors like Eldred Rock Partners LLC and Moody Lynn & Lieberson LLC have significantly raised their stakes in NVS, reflecting confidence in the company's long-term growth.
Analyst upgrades from firms such as JPMorgan and Bank of America have contributed to the optimistic shift in sentiment towards NVS, suggesting a potential upside in the stock price.
Despite varied analyst ratings and a minor earnings miss, strong institutional support and positive market outlook are likely propelling the bullish momentum in Novartis AG's stock today.

NVS Price Chart

NVS Technical Analysis

NVS News

D.A. Davidson & CO. Sells 106,074 Shares of Novartis AG $NVS

D.A. Davidson & CO. reduced its stake in Novartis AG (NYSE:NVS) by 32.1% in the third quarter, selling 106,074 shares and retaining 224,547 shares valued at approximately $28.8 million. While institutional investors like Fisher, Loomis Sayles, Goldman Sachs, Envestnet, and State Street increased their holdings, analyst sentiment for Novartis is mixed, with an average "Hold" rating and a target price of $119.75. The company's stock currently trades around $138.50, and recent earnings missed consensus estimates by a narrow margin.

https://www.marketbeat.com/instant-alerts/filing-da-davidson-co-sells-106074-shares-of-novartis-ag-nvs-2026-01-05/

Eldred Rock Partners LLC Has $11.64 Million Position in Novartis AG $NVS

Eldred Rock Partners LLC significantly increased its stake in Novartis AG (NYSE:NVS) by 12.2% in the third quarter, bringing its total holdings to 90,753 shares valued at $11.64 million, making it the 18th largest holding in their portfolio. Novartis reported Q3 EPS of $2.25, narrowly missing estimates, but revenues beat expectations at $14.36 billion, an 8.5% year-over-year increase. Despite a consensus "Hold" rating from analysts with a target price below its current share price, institutional investment in Novartis remains robust, with several firms adjusting their positions.

https://www.marketbeat.com/instant-alerts/filing-eldred-rock-partners-llc-has-1164-million-position-in-novartis-ag-nvs-2026-01-01/

Moody Lynn & Lieberson LLC Acquires 16,752 Shares of Novartis AG $NVS

Moody Lynn & Lieberson LLC significantly increased its stake in Novartis AG (NYSE:NVS) by 731.8% in Q3, adding 16,752 shares to hold a total of 19,041 shares valued at approximately $2.44 million. Analyst sentiment for Novartis has recently shown a positive shift with upgrades from JPMorgan and Bank of America, though the consensus remains a "Hold" with an average target price of $119.75. The company's stock trades near its 12-month high and holds a market capitalization of around $293 billion, despite a slight miss in EPS for its last quarterly earnings.

https://www.marketbeat.com/instant-alerts/filing-moody-lynn-lieberson-llc-acquires-16752-shares-of-novartis-ag-nvs-2025-12-31/

Novartis AG Price History

06.00.2026 - NVS Stock was up 3.5%

The bullish movement in Novartis AG (NVS) stock today is driven by increased institutional investment and positive sentiment from analysts following a recent earnings miss.
Institutional investors like Eldred Rock Partners LLC and Moody Lynn & Lieberson LLC have significantly raised their stakes in NVS, reflecting confidence in the company's long-term growth.
Analyst upgrades from firms such as JPMorgan and Bank of America have contributed to the optimistic shift in sentiment towards NVS, suggesting a potential upside in the stock price.
Despite varied analyst ratings and a minor earnings miss, strong institutional support and positive market outlook are likely propelling the bullish momentum in Novartis AG's stock today.

Disclaimer

Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.

Trade Novartis AG and 700+ other stocks, cryptocurrencies, commodities and more on Morpher. Sign up now and never miss out on the action again!

Date

Jan 6, 2026 19:15

Content

Novartis AG ($NVS) Stock Forecast: Up 3.5% Today What is Novartis AG? Why is Novartis AG going up? NVS NVS Price Chart NVS News Trending Today Novartis AG Price History 06.00.2026 - NVS Stock was up 3.5%